News

June 25, 2019June 25, 2019

Keytruda Found to be Safe as Cancer Treatment for HIV Patients, Phase 1 Trial Shows

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) was found to be a safe treatment for different cancer types among people living with HIV, data from a Phase 1 trial show. The results ... Read more

June 21, 2019

Bemcentinib-Keytruda Combo Provides Durable Response in Advanced NSCLC, Phase 2 Trial Shows

News

Combining bemcentinib with Keytruda (pembrolizumab) has shown efficacy and led to longer survival than previous second-line treatments in patients with advanced non-small cell lung cancer (NSCLC), according to updated ... Read more

June 19, 2019

FDA Grants Fast Track Status to Immunotherapy Candidate TRQ-1501 for Some Solid Tumors, Lymphomas

News

TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat ... Read more

June 18, 2019

Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show

News

A single dose of PolyPEPI1018 — Treos Bio’s investigational off-the-shelf vaccine for colorectal cancer — induced promising immune responses and clinical signs of efficacy when given in combination with ... Read more

June 14, 2019

Tecentriq Combo Prolongs Life of Lung Cancer Patients with Liver Metastases, Phase 3 Study Shows

News

Adding Tecentriq (atezolizumab) to a combination of Avastin (bevacizumab) and chemotherapy cut the risk of death by nearly half in a group of metastatic non-small cell lung cancer (NSCLC) ... Read more

June 12, 2019

FDA Approves Keytruda for Metastatic or Recurrent Head and Neck Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for patients with metastatic or recurrent and inoperable head and neck squamous cell carcinoma (HNSCC) ... Read more

June 11, 2019

Keytruda Improves Survival of Patients with Recurrent or Metastatic Head, Neck Cancer, Phase 3 Trial Shows

News

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care ... Read more

June 7, 2019

Imfinzi Still Improving Survival Rates in Advanced NSCLC Patients, PACIFIC Update Shows

News

AstraZeneca‘s Imfinzi (durvalumab) continues to demonstrate superior overall survival compared to placebo when given to patients with stage III, inoperable non-small-cell lung cancer (NSCLC) whose disease did not progress after platinum-based chemotherapy ... Read more

June 5, 2019

Kite’s Investigational CAR-T Cell Therapy Shows Promise in Phase 1/2 Trial

News

A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 ... Read more

June 4, 2019

Phase 1/2 Trial of Immunotherapy AGI-134 to Open to US Patients with Solid Tumors

News

BioLineRx is expanding the Phase 1/2 clinical trial of its investigational AGI-134 to include the U.S., now that regulatory officials there have approved the company’s request to test the ... Read more

Pin It on Pinterest